"Aurora Kinase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An aurora kinase that localizes to the CENTROSOME during MITOSIS and is involved in centrosome regulation and formation of the MITOTIC SPINDLE. Aurora A overexpression in many malignant tumor types suggests that it may be directly involved in NEOPLASTIC CELL TRANSFORMATION.
| Descriptor ID |
D064096
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.103.500 D12.776.167.049.500
|
| Concept/Terms |
Aurora Kinase A- Aurora Kinase A
- Aurora A Kinase
- Aurora A Kinases
- Aurora Kinases A
- STK15 Kinase
- AURORA2 Protein
- AuroraA Kinase
- Breast-Tumor-Amplified Kinase
- Breast Tumor Amplified Kinase
- BTAK Protein
- Serine-Threonine Protein Kinase 15
- Serine Threonine Protein Kinase 15
- AURKA
- Aurora-A Kinase
|
Below are MeSH descriptors whose meaning is more general than "Aurora Kinase A".
Below are MeSH descriptors whose meaning is more specific than "Aurora Kinase A".
This graph shows the total number of publications written about "Aurora Kinase A" by people in this website by year, and whether "Aurora Kinase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aurora Kinase A" by people in Profiles.
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 03 05; 17(826):eadh4475.
-
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro Oncol. 2023 02 14; 25(2):386-397.
-
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. Cancer Chemother Pharmacol. 2023 02; 91(2):191-201.
-
Integrative ontology and pathway-based approach identifies distinct molecular signatures in transcriptomes of esophageal squamous cell carcinoma. Adv Protein Chem Struct Biol. 2022; 131:177-206.
-
Aurora-A kinase is differentially expressed in the nucleus and cytoplasm in normal M?llerian epithelium and benign, borderline and malignant serous ovarian neoplasms. Diagn Pathol. 2021 Oct 27; 16(1):98.
-
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
-
Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci Rep. 2021 05 17; 11(1):10461.
-
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.
-
TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. Cancer Res. 2020 06 15; 80(12):2484-2497.
-
Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells. J Cell Sci. 2018 12 14; 131(24).